Filtered By:
Drug: Pradaxa
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 1528 results found since Jan 2013.
Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study
CONCLUSION: Among patients with AF and chronic liver disease, DOACs as a class were associated with lower risks of hospitalization for ischemic stroke/systemic embolism and major bleeding versus warfarin. However, the incidence of clinical outcomes among patients with AF and chronic liver disease varied between individual DOACs and warfarin, and in head-to-head DOAC comparisons.PMID:36762560 | DOI:10.1161/CIRCULATIONAHA.122.060687
Source: Circulation - February 10, 2023 Category: Cardiology Authors: Oluwadolapo D Lawal Herbert D Aronow Fisayomi Shobayo Anne L Hume Tracey H Taveira Kelly L Matson Yichi Zhang Xuerong Wen Source Type: research
Sex and gender differences in the use of oral anticoagulants for non-valvular atrial fibrillation: A population-based cohort study in primary health care in catalonia
Conclusion: We described the dose adequacy of patients receiving DOAC, finding a high frequency of underdosing, and significantly higher in women in comparison with men. Adherence was generally high, only with higher levels in women for rivaroxaban. Persistence during the first year of treatment was also high in general, being significantly more persistent women than men in the case of dabigatran and edoxaban. Dose inadequacy, lack of adherence and of persistence can result in less effective and safe treatments. It is necessary to conduct studies analysing sex and gender differences in health and disease.
Source: Frontiers in Pharmacology - February 7, 2023 Category: Drugs & Pharmacology Source Type: research
Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke
Conclusion: Reversal of dabigatran with idarucizumab in stroke patients appears easy to manage, safe and beneficial. The SOPs aim to reassure stroke physicians to include dabigatran reversal into their daily clinical routine when dealing with patients presenting with ischemic or hemorrhagic stroke under dabigatran therapy.
Source: Journal of Thrombosis and Thrombolysis - February 4, 2023 Category: Hematology Source Type: research
Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country
ConclusionsIn a developing country where suboptimal anticoagulation control is common, apixaban was the cost-effective alternative to warfarin for patients with both low and intermediate TTR control.
Source: American Journal of Cardiovascular Drugs - February 3, 2023 Category: Cardiology Source Type: research
Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
Conclusion: NOACs had better long-term risk-benefit profiles than VKAs. While effectiveness was comparable, apixaban was overall associated with a more favorable safety profile followed by dabigatran.
Source: Frontiers in Pharmacology - February 2, 2023 Category: Drugs & Pharmacology Source Type: research
IJERPH, Vol. 20, Pages 2359: Integrated Machine Learning Decision Tree Model for Risk Evaluation in Patients with Non-Valvular Atrial Fibrillation When Taking Different Doses of Dabigatran
hi-Jie Lu
The new generation of nonvitamin K antagonists are broadly applied for stroke prevention due to their notable efficacy and safety. Our study aimed to develop a suggestive utilization of dabigatran through an integrated machine learning (ML) decision-tree model. Participants taking different doses of dabigatran in the Randomized Evaluation of Long-Term Anticoagulant Therapy trial were included in our analysis and defined as the 110 mg and 150 mg groups. The proposed scheme integrated ML methods, namely naive Bayes, random forest (RF), classification and regression tree (CART), and extreme gradient boosting (XG...
Source: International Journal of Environmental Research and Public Health - January 29, 2023 Category: Environmental Health Authors: Yung-Chuan Huang Yu-Chen Cheng Mao-Jhen Jhou Mingchih Chen Chi-Jie Lu Tags: Article Source Type: research
Impact of Rabeprazole on APO-Dabigatran Exposure in Healthy Volunteers
CONCLUSIONS: When APO-dabigatran is administered with rabeprazole, the exposure to dabigatran is reduced by about 30%, which is similar to the level observed with Pradaxa when it was co-administered with a proton pump inhibitor. However, the finding that one-third of participants had a > 50% reduction in exposure is concerning, and it highlights the need for caution in patients who have, or are at risk of, reduced gastric acidity.PMID:36700178 | PMC:PMC9869351 | DOI:10.1016/j.cjco.2022.09.006
Source: Atherosclerosis - January 26, 2023 Category: Cardiology Authors: Noel Chan Matt Wheeler Vinai Bhagirath Jacqueline Bosch Jutta Heinrich-Nols Debbie Sloane Joanne van Ryn Linda Jefferies Jacqueline Wilkinson Qilong Yi John Eikelboom Source Type: research
Stroke thrombolysis in a patient on dabigatran in the extended time window
N Z Med J. 2022 Jan 20;136(1568):105-108.NO ABSTRACTPMID:36657080
Source: New Zealand Medical Journal - January 19, 2023 Category: General Medicine Authors: Stewart Shiu Bobae Lee Karim M Mahawish Source Type: research
